← Back to Search

AIRVO 2; new asymmetric nasal cannula for Chronic Obstructive Pulmonary Disease

Q: Can new participants still join this research endeavor?

<p>As per clinicaltrials.gov, this <a href="https://www.withpower.com/clinical-trials/experimental">experimental</a> trial is currently recruiting participants. This research project was originally registered on May 25th 2022 and its details were recently modified on July 11th 2022.</p>

Q: How many individuals are under the scrutiny of this clinical experiment?

<p>Affirmative. Clinicaltrials.gov states that this clinical survey is recruiting participants, with the original post on May 25th 2022 and last update July 11th 2022. Altogether, 12 individuals must be found from one centre for inclusion in the study.</p>

N/A

Waitlist Available

Led By Gerard J Criner, MD

Research Sponsored by Temple University

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

i.aged ≥ 40 years (ii) hospitalization for acute exacerbation of COPD; (iii) smoker or ex-smoker (iv) FEV1 <80% of predicted and FEV1/FVC <70% postbronchodilator within 12 months prior to admission (v) have no other lung disease (including asthma) as a principal cause of pulmonary function limitation (vi) baseline PaCO2 ≥ 45 mm Hg at study entry. (vii) willing to give informed consent (viii) willing to participate in measurement of ABGs (ix) will to provide a brief history and physical examination and answer questionnaires.

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 hours

Awards & highlights

Study Summary

This trial will assess the impact of a new nasal cannula with asymmetric cannula dimensions on patient comfort, vital signs, pulse oximetry, breathing pattern and parameters of gas exchange in hospitalized patients with a COPD exacerbation.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 hours

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 hours

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 hours for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Determining the level of comfort experienced by the patient of using high-flow nasal oxygen administered by two different nasal cannulas.

Sensation of shortness of breath

Trial Design

2Treatment groups

Active Control

Group I: AIRVO 2; new asymmetric nasal cannulaActive Control1 Intervention

The patient's breathing pattern will be assessed by inductive plethysmography while using the cannula and receive HFNT for 2 hours during the first session. Patients will then be randomized to use of the conventional symmetric nasal cannula or the new asymmetric nasal cannula. At the end of the first session questionnaire data will be collected and ABGs will be repeated followed by a 30-minute rest period without any device. Patients will then crossover to receive HFNT via the other cannula type for another 2 hours during the second session. Inductive plethysmography will again be worn and ABGs will be obtained, and questionnaires will again be administered

Group II: Conventional symmetric nasal cannulaActive Control1 Intervention

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Temple UniversityLead Sponsor

296 Previous Clinical Trials

82,781 Total Patients Enrolled

Fisher and Paykel HealthcareIndustry Sponsor

120 Previous Clinical Trials

9,934 Total Patients Enrolled

Gerard J Criner, MDPrincipal InvestigatorTemple University

5 Previous Clinical Trials

2,110 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can new participants still join this research endeavor?

"As per clinicaltrials.gov, this experimental trial is currently recruiting participants. This research project was originally registered on May 25th 2022 and its details were recently modified on July 11th 2022."

Answered by AI

How many individuals are under the scrutiny of this clinical experiment?

"Affirmative. Clinicaltrials.gov states that this clinical survey is recruiting participants, with the original post on May 25th 2022 and last update July 11th 2022. Altogether, 12 individuals must be found from one centre for inclusion in the study."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Tolerance and Acute Effects of a New HFNT Nasal Cannula

Gerard Criner 2022. "Tolerance and Acute Effects of a New HFNT Nasal Cannula". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05182294.